Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Post by narcissiston Sep 08, 2011 10:10am
482 Views
Post# 19021993

psoriasis news

psoriasis newsThis is a significant survey result. Study is posted here:

https://www.marketwatch.com/story/at-least-one-half-of-surveyed-european-dermatologists-say-they-are-likely-to-delay-their-prescribing-of-tofacitinib-until-it-has-accumulated-favorable-postmarketing-safety-data-2011-09-08

"The new European Physician & Payer Forum report entitled European Physician and Payer Perspectives on Emerging Immunomodulators in Psoriasis also finds that the majority of surveyed dermatologists in the EU5 indicate that they will prescribe Isotechnika's emerging calcinuerin inhibitor voclosporin, following its launch for psoriasis."
<< Previous
Bullboard Posts
Next >>